<DOC>
	<DOCNO>NCT01318122</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety efficacy alogliptin Thiazolidine administer daily ( QD ) 40 consecutive week participant complete phase 2/3 Thiazolidine add study .</brief_summary>
	<brief_title>Long-term Safety Study Alogliptin Used Combination With Thiazolidine Participants With Type 2 Diabetes Japan</brief_title>
	<detailed_description>Both insulin hyposecretion insulin-resistance consider involved development type 2 diabetes mellitus . Takeda develop SYR-322 ( alogliptin ) improvement glycemic control patient type 2 diabetes mellitus . Alogliptin inhibitor dipeptidyl peptidase IV ( DPP-IV ) enzyme . DPP-IV think primarily responsible degradation 2 peptide hormone release response nutrient ingestion . It expect inhibition DPP-IV improve glycemic control patient type 2 diabetes . To evaluate long-term safety efficacy alogliptin , participant present study enrol core phase 2/3 thiazolidine add study ( SYR-322/CCT-004 ; NCT01318070 ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<criteria>1 . Had complete core phase 2/3 thiazolidine add study . 2 . The subject capable understanding comply protocol requirement . 3 . Signed write , informed consent form prior initiation study procedure . 1 . With clinical manifestation hepatic impairment ( e.g. , AST ALT value 2.5 time upper reference limit Week 8 core phase 2/3 thiazolidine add study ) . 2 . With clinical manifestation renal impairment ( e.g. , creatinine value 2 mg/dL Week 8 core phase 2/3 thiazolidine add study ) . 3 . With history symptom cardiac failure .</criteria>
	<gender>All</gender>
	<minimum_age>33 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Diabetes Mellitus - Type 2</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>